AI-generated summary
The authors compared three photobiomodulation protocols at 660 nm in 73 patients receiving radiotherapy for head and neck cancer. The protocol starting on day one at 15 mW and 3.8 J/cm2 was reported to delay grade II oral mucositis and to give lower pain scores than the other two protocols.
- Participants
- 73
- Who or what was studied
- Patients with cancer of the oral cavity, oropharynx, or nasopharynx receiving radiotherapy to facial fields of 6000 cGy or more
- Wavelengths
- 660 nm
- Limits stated in the abstract
- Abstract reports a single randomized comparison with no stated details on blinding, and the authors' conclusion of greater effectiveness rests on relative differences between three arms.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Energy density (fluence)
- 3.8 J/cm2, 6.3 J/cm2
- Power
- 15 mW, 25 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Oral mucositis, Photobiomodulation, GRADE, Dose, Visual analogue scale. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.